home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

27.14 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 27, 2024

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Via Benzinga

Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday ↗

February 27, 2024

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

Via Benzinga

Topics Stocks

Recap: Beam Therapeutics Q4 Earnings ↗

February 27, 2024

Via Benzinga

Is Beam Therapeutics Stock a Buy Now? ↗

November 18, 2023

It has plenty of money, but it'll be facing plenty of competition, too.

Via The Motley Fool

Beam Therapeutics Inc. (NASDAQ: BEAM) Leading the Way in Tuesday Trading Based on Percentage Gain

February 27, 2024

Via Investor Brand Network

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

February 27, 2024

From Beam Therapeutics

Via GlobeNewswire

Is CRISPR Therapeutics the NVIDIA of gene editing?

February 26, 2024

CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv

Via MarketBeat

Topics Artificial Intelligence

Beam Therapeutics Stock Shows Healthy Relative Strength Improvement ↗

February 16, 2024

In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday.

Via Investor's Business Daily

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Via MarketBeat

Topics Artificial Intelligence

Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss ↗

February 08, 2024

Via Benzinga

3 Biotech Stocks to Buy on the Dip: February 2024 ↗

February 07, 2024

Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities

Via InvestorPlace

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 05, 2024

From Beam Therapeutics

Via GlobeNewswire

Why Beam Therapeutics Stock Zoomed 17% Higher Today ↗

January 29, 2024

JPMorgan Chase becomes the latest institution in the company's bull pen.

Via The Motley Fool

2 gene editing stocks to keep on your 2024 watchlist

January 23, 2024

Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

Via MarketBeat

Bitcoin, Ethereum, Dogecoin Rise As Investors Weigh Spot ETF Impact: Analyst Says Scenario For King Crypto Is 'Rejection' At $46K And Then Correction To Below $40K ↗

January 16, 2024

Major cryptocurrencies on Tuesday evening posted some gains following a weekend characterized by

Via Benzinga

Topics ETFs

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market ↗

January 16, 2024

Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.

Via InvestorPlace

3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street ↗

January 16, 2024

Analysts have high hopes for these three innovation companies in 2024.

Via The Motley Fool

3 Stocks to Buy in the Booming Field of Gene Editing ↗

January 11, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

Via InvestorPlace

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

January 08, 2024

From Beam Therapeutics

Via GlobeNewswire

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 ↗

January 08, 2024

Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.

Via The Motley Fool

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Beam Therapeutics

Via GlobeNewswire

2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street ↗

December 27, 2023

Wall Street is uber-bullish on these two Ark Invest holdings.

Via The Motley Fool

CRISPR Therapeutics sets sights on gene-editing cures for disease

December 27, 2023

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

Via MarketBeat

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

December 14, 2023

From Beam Therapeutics

Via GlobeNewswire

Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 08, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception ↗

November 29, 2023

The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014.

Via Benzinga

Topics ETFs

The 3 Best Gene Editing Stocks on the Frontier of Medicine ↗

November 20, 2023

Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.

Via InvestorPlace

3 Monster Stocks in the Making ↗

November 18, 2023

These stocks could grow much larger over the next few years.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com